WorldCare Clinical's WorldPRO Suite Evolves to Support Complex Endpoint Assessment Committee Reviews
WorldCare Clinical
announced a major release of its WorldPRO image management platform, a comprehensive system that collects, integrates and presents data to multiple reviewers in a regulatory compliant, efficient and effective manner. With the new version of WorldPRO, multiple clinicians can now access and evaluate data in preparation of an endpoint assessment committee review.
"We’re seeing an increase in the use of EACs, particularly in oncology trials, partially in response to regulatory agencies looking for an integrated assessment of patient outcomes," said Richard Walovitch, PhD, president of WorldCare Clinical, LLC. "The enhancements we’ve made to our WorldPRO platform ensures that sponsors can benefit from a holistic assessment of disease. Leveraging our relationship with Massachusetts General Hospital, we are able to provide oncology, pathology, dermatology, and oncology reviews by clinicians who apply practices used in patient care to the clinical trial setting."
By providing fully automated functionality for imaging data management, cli nical data management, image analysis, project management, and full trial transparency in a 21 CRF-compliant solution, the WorldPRO platform streamlines and improves the blinded independent central review (BICR) process by ensuring sponsors have complete control over trial data every step of the way.
The latest version includes updated features designed to further enhance the flexibility and configurability of WorldPRO to accommodate complex workflows, integrating the review of radiology, pathology, photography, and clinical data. This integration enables a more efficient review, reducing study timelines and improving data accuracy. In addition to delivering significant operational efficiencies to sponsors, WorldPRO provides complete transparency throughout the course of a trial by enabling sponsors to confirm that all data has been properly obtained and received from investigators before final blinded assessment, and minimizes unnecessary re-reads that can negatively impact chances for FDA approval. WCC’s fully digital process removes bias in data handling, and an efficient data management system streamlines all data capture and transmission to optimize workflow and ensure total control throughout.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
